MiR-873/PD-L1 axis regulates the stemness of breast cancer cells

EBioMedicine
Lanlan GaoLufeng Zheng

Abstract

Breast cancer stem cells have self-renewal capability and are resistant to conventional chemotherapy. PD-L1 could promote the expression of stemness markers (OCT4 and Nanog) in breast cancer stem cells. However, the mechanisms by which PD-L1 regulates the stemness of breast cancer cells and PD-L1 is regulated in breast cancer cells are still unclear. Lentivirus infection was used to construct stable cell lines. The correlation between PD-L1 and stemness markers expression was evaluated in clinical samples. Additionally, luciferase reporter assay combined with RNA-Fluorescence in situ hybridization (RNA-FISH) and RNA-binding protein immunoprecipitation (RIP) assays were used to verify the direct binding of miR-873 on PD-L1. Furthermore, flow cytometry, mammosphere formation combined with nude mouse tumor xenograft model were carried out to examine the effects of miR-873/PD-L1 axis on the stemness of breast cancer cells. Finally, MTT assay was performed to determine the effects of miR-873/PD-L1 axis on drug resistance. PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K...Continue Reading

Citations

Apr 28, 2020·The Journal of International Medical Research·Yuling GuoZhengyu Zhan
Jun 20, 2019·Frontiers in Immunology·Silvia PesceEmanuela Marcenaro
Oct 23, 2019·Frontiers in Immunology·Weiting QinXu Wang
Dec 13, 2019·The Journal of Gene Medicine·Yu ChenManyu Chen
Mar 13, 2020·Frontiers in Cell and Developmental Biology·Silvia PesceEmanuela Marcenaro
Dec 22, 2019·Cells·Xueqiao JiaoLixia Xiong
Mar 31, 2020·Journal of Hematology & Oncology·Ming YiKongming Wu
Nov 22, 2019·Pathology Oncology Research : POR·Lei DingYanli Li
Jul 28, 2020·Biomolecules·Alexandre PerrierSimon Garinet
Jun 21, 2020·Signal Transduction and Targeted Therapy·Lei LiuShouping Xu
Jan 7, 2021·Cell Reports·Peiwen ChenRonald A DePinho
Jan 9, 2021·Journal of Hematology & Oncology·Ming YiKongming Wu
Nov 19, 2020·Breast Cancer : Targets and Therapy·Andrea Luque-BolivarMilena Rondón-Lagos
Jan 21, 2021·International Journal of Molecular Sciences·Yueyuan ZhouTakahiro Ochiya
Feb 19, 2021·Regenerative Therapy·Kosuke YoshidaTakahiro Ochiya
Mar 20, 2021·Seminars in Cancer Biology·Rui ZhangSuling Liu
Apr 4, 2021·Biomolecules·Nadia Flores-HuertaCésar López-Camarillo
Apr 19, 2021·Seminars in Cell & Developmental Biology·Priya MondalSyed Musthapa Meeran
Apr 21, 2021·Seminars in Cell & Developmental Biology·Deepti SinghHifzur R Siddique
May 25, 2021·Frontiers in Oncology·Anna Maria GrimaldiMariarosaria Incoronato
Jun 6, 2021·Journal of Experimental & Clinical Cancer Research : CR·Hao ZhangQuan Cheng
Jun 7, 2021·Stem Cell Research & Therapy·Haiwei NiLufeng Zheng
Jun 15, 2021·Frontiers in Immunology·Khalil KhalafMariusz Kaczmarek
Aug 8, 2021·International Journal of Molecular Sciences·Hsing-Ju Wu, Pei-Yi Chu
Aug 10, 2021·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Yu ZhangMinfeng Ye
Aug 9, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Behnia AkbariHamid Reza Mirzaei
Sep 16, 2021·Cancer Metastasis Reviews·Iris Garrido-CanoPilar Eroles
Oct 17, 2021·Journal of Hematology & Oncology·Yiyin ZhangHui Lin

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
PCR
flow cytometry
immunoprecipitation assay
confocal microscopy
xenograft
RIP

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.